Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma
NCT ID: NCT05451134
Last Updated: 2022-07-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2022-06-30
2022-07-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Severe Intraoperative Hyperglycemia During Craniotomy and Postoperative Infections
NCT02165748
Diagnosing and Treating Low Blood Sugar Levels
NCT00001276
18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism
NCT04205604
Treatment of Hypoglycemia Following Gastric Bypass Surgery
NCT02527993
Hypoglycemia and the Mineralocorticoid Receptor
NCT01394627
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with dysglycemia
Patients with dysglycemia in the included subjects with pheochromocytoma and paraganglioma
Catecholamines
Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma
patients without dysglycemia
Patients without dysglycemia in the included subjects with pheochromocytoma and paraganglioma
Catecholamines
Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Catecholamines
Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients with surgical pathological diagnosis of pheochromocytomas and paragangliomas(PPGLs)
Exclusion Criteria
* patients who required steroids after adrenalectomy
* patients with inadequate clinical records were excluded.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking Union Medical College Hospital
OTHER
China National Center for Cardiovascular Diseases
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xian-Liang Zhou
Role: PRINCIPAL_INVESTIGATOR
National Center for Cardiovascular Diseases; Fuwai Hospital, Chinese Academy of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xian-Liang Zhou
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.